BioNTech SE (BNTX) Company Overview

Stocks of vaccine companies dropped after a Senate committee decided to move forward with Robert F. Kennedy Jr.'s nomination to head the Department of Health and Human Services for a full vote.

MAINZ, Germany, February 3, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) has announced that it has completed the acquisition of Biotheus, a biotechnology company focused on creating new antibodies for patients with cancer or inflammatory diseases. This acquisition, which was first revealed in November 2024, follows a successful partnership on the late-stage clinical product BNT327, a bispecific antibody aimed at PD-L1 and VEGF-A, along with other similar candidates.

How high are stock prices at the moment? BioNTech (NASDAQ: BNTX) gained attention in 2020 when it partnered with Pfizer to create a COVID-19 vaccine. Now, BioNTech has grown significantly and has a market value of about $27 billion.

How costly is the stock market at the moment? The S&P 500 Shiller CAPE ratio is close to its second-highest point in history.

Wall Street analysts have set an average price target for BioNTech (BNTX) that suggests a possible increase of 25.6%. Although the reliability of this popular measure is debatable, the recent positive changes in earnings estimates could lead to a rise in the stock's value.

Almost a year ago, I shared four forecasts regarding the stock market for 2024. I expected the S&P 500 to have positive returns, but not as high as those in 2023.

BioNTech announced on Friday that it has reached two different settlement agreements with the U.S. National Institutes of Health and the University of Pennsylvania regarding royalty payments for its COVID-19 vaccine.

Investing in biotech stocks can be quite risky and is not for everyone. These stocks often experience significant price fluctuations due to the challenges involved in creating new medications.

On Friday, BioNTech SE announced that its partner OncoC4 has told them that the U.S. Food and Drug Administration has removed the partial clinical hold on their advanced trial for a lung cancer treatment.